Camizestrant, development code AZD9833, is a next-generation oral selective estrogen receptor degrader (SERD) developed by AstraZeneca is under clinical investigation for ER-positive breast cancer. It is one of the leading SERD candidates in oncology research.
As a dedicated supplier of pharmaceutical intermediates and APIs,
EOS Med CDMO offers Camizestrant for research and development use, We support scale-up production up to kilogram levels and provide full Drug Master File (DMF) documentation support. Every shipment comes with complete technical dossiers, including COA, MSDS, and analytical data (HPLC/HNMR), to ensure seamless regulatory compliance for your project.
Supply Capability
stock: 571g
Purity:99.3%
Production: GMP-compliant facility
Documentation (on request): COA / HNMR / MSDS / DMF support
Specifications
CAS: 2222844-89-3
Synonyms: AZD9833
Target: SERD (oral estrogen receptor degrader)
Research Area: ER+ breast cancer
Transportation Conditions: This product is a non-hazardous chemical and should be transported at room temperature. It can be stably stored for several weeks during normal transportation and customs clearance.
Storage Conditions: Short-term (days to weeks) storage at 0-4°C; long-term (months to years) storage at -20°C.
Solubility: To be determined.
Shelf Life: Over 2 years under proper storage conditions.
Pharmaceutical Preparations: To be determined.
Catalyst Storage: Short-term (days to weeks) storage at 0-4°C; long-term (months) storage at -20°C.
HS Code: 2934.99.9001